Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

Phase 3

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: carboplatin
Drug: temozolomide
Drug: cisplatin
Drug: thiotepa
Drug: cyclophosphamide
Drug: vincristine sulfate
Drug: etoposide
Procedure: autologous bone marrow transplantation
Drug: methotrexate
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2006-10-26

Last Posted Date: 2013-12-18

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 120

Registration Number: NCT00392886

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇦🇺
Princess Margaret Hospital for Children, Perth, Western Australia, Australia
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 34 locations

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Phase 3

Active, not recruiting

Conditions: Anaplastic Medulloblastoma
Medulloblastoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Procedure: Lumbar Puncture
Biological: Filgrastim
Drug: Isotretinoin
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Vincristine Sulfate

First Posted Date: 2006-10-26

Last Posted Date: 2024-01-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 379

Registration Number: NCT00392327

Locations: 🇺🇸
Inova Fairfax Hospital, Falls Church, Virginia, United States
🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
🇵🇷
University Pediatric Hospital, San Juan, Puerto Rico

and more 182 locations

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Erlotinib
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: 5-FU
Procedure: Radiation therapy
Procedure: Surgery

First Posted Date: 2006-10-26

Last Posted Date: 2022-03-02

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 62

Registration Number: NCT00393068

Locations: 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 6 locations

Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Neoplasms
Peritoneal Neoplasm

Interventions: Drug: carboplatin
Drug: enzastaurin
Drug: placebo
Drug: paclitaxel

First Posted Date: 2006-10-23

Last Posted Date: 2020-10-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 153

Registration Number: NCT00391118

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Sorafenib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-10-20

Last Posted Date: 2014-12-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 85

Registration Number: NCT00390611

Locations: 🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Holy Cross Hospital, Ft. Lauderdale, Florida, United States

and more 14 locations

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Phase 1

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Pazopanib
Drug: paclitaxel
Drug: Lapatinib
Drug: carboplatin

First Posted Date: 2006-10-13

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 86

Registration Number: NCT00388076

Locations: 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States

Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: irinotecan

First Posted Date: 2006-10-13

Last Posted Date: 2018-01-10

Lead Sponsor: University of California, Davis

Target Recruit Count: 80

Registration Number: NCT00387660

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

Phase 2

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Stage IIIB Non-small Cell Lung Cancer
Adenosquamous Cell Lung Cancer
Hemoptysis
Squamous Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Biological: bevacizumab
Drug: paclitaxel
Drug: carboplatin
Radiation: radiation therapy

First Posted Date: 2006-10-13

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00387374

Locations: California Cancer Consortium

A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer

Phase 2

Terminated

Conditions: Esophageal Neoplasms

Interventions: Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2006-10-03

Last Posted Date: 2016-01-11

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 9

Registration Number: NCT00383266

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Phase 3

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Neoplasms
Ovarian Cancer

Interventions: Drug: carboplatin
Drug: phenoxodiol
Drug: placebo

First Posted Date: 2006-10-02

Last Posted Date: 2016-07-18

Lead Sponsor: MEI Pharma, Inc.

Target Recruit Count: 142

Registration Number: NCT00382811

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Associates in Women's Health, Wichita, Kansas, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 67 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy